Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer's Blood Test

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at uk.finance.yahoo.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

Roche Holding has received FDA clearance for a blood test that detects Alzheimer's disease, marking a significant regulatory milestone in diagnostic tools for neurodegenerative conditions.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 4 sources have reported it between 24 Aug 2026 and 28 Aug 2026.

◆ ◆ The Wire takeaway

Alzheimer's diagnostic tech just gained a clear route to US clinical use with FDA approval. You can now explore faster market entry or partnerships based on this newly cleared blood test approach.

◆ Coverage

4 sources · first reported 24 Aug 2026 · latest 28 Aug 2026

◆ Related on Wire

◆ Topics

DiagnosticsalzheimersdiagnosticsFDA-clearanceblood-testhealthtech